A Single Arm, Open, Phase I/II Clinical Study of MASCT-I Treatment for Advanced Solid Tumor
Latest Information Update: 15 Nov 2019
At a glance
- Drugs MASCT I (Primary)
- Indications Colon cancer; Lung cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 31 May 2019 Results of pooled analysis of two prospective trials (NCT02844881; NCT02858232) assess the toxicity and efficacy of PD-1 blockade (SHR-1210)-activated MASCT (aMASCT) alone or in combination with apatinib published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2016 New trial record